Document Leak: NICE Says No to MS
Pharmaceutical Executive
London-Schering and Biogen have both expressed anger over the leak of a National Institute of Clinical Excellence (NICE) document suggesting that doctors stop prescribing beta-interferon to new multiple sclerosis (MS) patients.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
